A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease
Identifieur interne : 000408 ( Main/Exploration ); précédent : 000407; suivant : 000409A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease
Auteurs : Catherine L. Gallagher [États-Unis] ; Bradley T. Christian [États-Unis] ; James E. Holden [États-Unis] ; Onofre T. Dejesus [États-Unis] ; Robert J. Nickles [États-Unis] ; Laura Buyan-Dent [États-Unis] ; Barbara B. Bendlin [États-Unis] ; Sandra J. Harding [États-Unis] ; Charles K. Stone [États-Unis] ; Barb Mueller [États-Unis] ; Sterling C. Johnson [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-09.
English descriptors
Abstract
Progression of Parkinson's disease symptoms is imperfectly correlated with positron emission tomography biomarkers for dopamine biosynthetic pathways. The radiopharmaceutical 6‐[18F]fluoro‐m‐tyrosine is not a substrate for catechol‐O‐methyltransferase and therefore has a more favorable uptake‐to‐background ratio than 6‐[18F]fluoro‐L‐dopa. The objective of this study was to evaluate 6‐[18F]fluoro‐m‐tyrosine relative to 6‐[18F]fluoro‐L‐dopa with partial catechol‐O‐methyltransferase inhibition as a biomarker for clinical status in Parkinson's disease. Twelve patients with early‐stage Parkinson's disease, off medication, underwent Unified Parkinson Disease Rating Scale scoring, brain magnetic resonance imaging, and 3‐dimensional dynamic positron emission tomography using equivalent doses of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa with tolcapone, a catechol‐O‐methyltransferase inhibitor. Images were realigned within subject, after which the tissue‐derived uptake rate constant was generated for volumes of interest encompassing the caudate nucleus, putamen, and subregions of the putamen. We computed both bivariate (Pearson) and partial (covariate of age) correlations between clinical subscores and tissue‐derived uptake rate constant. Tissue‐derived uptake rate constant values were correlated between the radiopharmaceuticals (r = 0.8). Motor subscores were inversely correlated with the contralateral putamen 6‐[18F]fluoro‐m‐tyrosine tissue‐derived uptake rate constant (|r| > 0.72, P < .005) but not significantly with the 6‐[18F]fluoro‐L‐dopa tissue‐derived uptake rate constant. The uptake rate constants for both radiopharmaceuticals were also inversely correlated with activities of daily living subscores, but the magnitude of correlation coefficients was greater for 6‐[18F]fluoro‐m‐tyrosine. In this design, 6‐[18F]fluoro‐m‐tyrosine uptake better reflected clinical status than did 6‐[18F]fluoro‐L‐dopa uptake. We attribute this finding to 6‐[18F]fluoro‐m‐tyrosine's higher affinity for the target, L‐aromatic amino acid decarboxylase, and the absence of other major determinants of the uptake rate constant. These results also imply that L‐aromatic amino acid decarboxylase activity is a major determinant of clinical status. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23778
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease</title><author><name sortKey="Gallagher, Catherine L" sort="Gallagher, Catherine L" uniqKey="Gallagher C" first="Catherine L." last="Gallagher">Catherine L. Gallagher</name></author><author><name sortKey="Christian, Bradley T" sort="Christian, Bradley T" uniqKey="Christian B" first="Bradley T." last="Christian">Bradley T. Christian</name></author><author><name sortKey="Holden, James E" sort="Holden, James E" uniqKey="Holden J" first="James E." last="Holden">James E. Holden</name></author><author><name sortKey="Dejesus, Onofre T" sort="Dejesus, Onofre T" uniqKey="Dejesus O" first="Onofre T." last="Dejesus">Onofre T. Dejesus</name></author><author><name sortKey="Nickles, Robert J" sort="Nickles, Robert J" uniqKey="Nickles R" first="Robert J." last="Nickles">Robert J. Nickles</name></author><author><name sortKey="Buyan Ent, Laura" sort="Buyan Ent, Laura" uniqKey="Buyan Ent L" first="Laura" last="Buyan-Dent">Laura Buyan-Dent</name></author><author><name sortKey="Bendlin, Barbara B" sort="Bendlin, Barbara B" uniqKey="Bendlin B" first="Barbara B." last="Bendlin">Barbara B. Bendlin</name></author><author><name sortKey="Harding, Sandra J" sort="Harding, Sandra J" uniqKey="Harding S" first="Sandra J." last="Harding">Sandra J. Harding</name></author><author><name sortKey="Stone, Charles K" sort="Stone, Charles K" uniqKey="Stone C" first="Charles K." last="Stone">Charles K. Stone</name></author><author><name sortKey="Mueller, Barb" sort="Mueller, Barb" uniqKey="Mueller B" first="Barb" last="Mueller">Barb Mueller</name></author><author><name sortKey="Johnson, Sterling C" sort="Johnson, Sterling C" uniqKey="Johnson S" first="Sterling C." last="Johnson">Sterling C. Johnson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:522EE64365D119496B962B5766EE5C0A818FA428</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23778</idno><idno type="url">https://api.istex.fr/document/522EE64365D119496B962B5766EE5C0A818FA428/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000950</idno><idno type="wicri:Area/Main/Curation">000826</idno><idno type="wicri:Area/Main/Exploration">000408</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease</title><author><name sortKey="Gallagher, Catherine L" sort="Gallagher, Catherine L" uniqKey="Gallagher C" first="Catherine L." last="Gallagher">Catherine L. Gallagher</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>William S. Middleton Veterans Hospital, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Christian, Bradley T" sort="Christian, Bradley T" uniqKey="Christian B" first="Bradley T." last="Christian">Bradley T. Christian</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Wisconsin, Department of Medical Physics, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Waisman Laboratory for Brain Imaging and Behavior, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Holden, James E" sort="Holden, James E" uniqKey="Holden J" first="James E." last="Holden">James E. Holden</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Wisconsin, Department of Medical Physics, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Dejesus, Onofre T" sort="Dejesus, Onofre T" uniqKey="Dejesus O" first="Onofre T." last="Dejesus">Onofre T. Dejesus</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Wisconsin, Department of Medical Physics, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Nickles, Robert J" sort="Nickles, Robert J" uniqKey="Nickles R" first="Robert J." last="Nickles">Robert J. Nickles</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Wisconsin, Department of Medical Physics, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Buyan Ent, Laura" sort="Buyan Ent, Laura" uniqKey="Buyan Ent L" first="Laura" last="Buyan-Dent">Laura Buyan-Dent</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Bendlin, Barbara B" sort="Bendlin, Barbara B" uniqKey="Bendlin B" first="Barbara B." last="Bendlin">Barbara B. Bendlin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>William S. Middleton Veterans Hospital G.R.E.C.C., Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Harding, Sandra J" sort="Harding, Sandra J" uniqKey="Harding S" first="Sandra J." last="Harding">Sandra J. Harding</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>William S. Middleton Veterans Hospital G.R.E.C.C., Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Stone, Charles K" sort="Stone, Charles K" uniqKey="Stone C" first="Charles K." last="Stone">Charles K. Stone</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Mueller, Barb" sort="Mueller, Barb" uniqKey="Mueller B" first="Barb" last="Mueller">Barb Mueller</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Waisman Laboratory for Brain Imaging and Behavior, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Johnson, Sterling C" sort="Johnson, Sterling C" uniqKey="Johnson S" first="Sterling C." last="Johnson">Sterling C. Johnson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>William S. Middleton Veterans Hospital G.R.E.C.C., Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-09">2011-09</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="2032">2032</biblScope><biblScope unit="page" to="2038">2038</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">522EE64365D119496B962B5766EE5C0A818FA428</idno><idno type="DOI">10.1002/mds.23778</idno><idno type="ArticleID">MDS23778</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease/radionuclide imaging</term><term>dopamine/metabolism</term><term>positron emission tomography</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Progression of Parkinson's disease symptoms is imperfectly correlated with positron emission tomography biomarkers for dopamine biosynthetic pathways. The radiopharmaceutical 6‐[18F]fluoro‐m‐tyrosine is not a substrate for catechol‐O‐methyltransferase and therefore has a more favorable uptake‐to‐background ratio than 6‐[18F]fluoro‐L‐dopa. The objective of this study was to evaluate 6‐[18F]fluoro‐m‐tyrosine relative to 6‐[18F]fluoro‐L‐dopa with partial catechol‐O‐methyltransferase inhibition as a biomarker for clinical status in Parkinson's disease. Twelve patients with early‐stage Parkinson's disease, off medication, underwent Unified Parkinson Disease Rating Scale scoring, brain magnetic resonance imaging, and 3‐dimensional dynamic positron emission tomography using equivalent doses of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa with tolcapone, a catechol‐O‐methyltransferase inhibitor. Images were realigned within subject, after which the tissue‐derived uptake rate constant was generated for volumes of interest encompassing the caudate nucleus, putamen, and subregions of the putamen. We computed both bivariate (Pearson) and partial (covariate of age) correlations between clinical subscores and tissue‐derived uptake rate constant. Tissue‐derived uptake rate constant values were correlated between the radiopharmaceuticals (r = 0.8). Motor subscores were inversely correlated with the contralateral putamen 6‐[18F]fluoro‐m‐tyrosine tissue‐derived uptake rate constant (|r| > 0.72, P < .005) but not significantly with the 6‐[18F]fluoro‐L‐dopa tissue‐derived uptake rate constant. The uptake rate constants for both radiopharmaceuticals were also inversely correlated with activities of daily living subscores, but the magnitude of correlation coefficients was greater for 6‐[18F]fluoro‐m‐tyrosine. In this design, 6‐[18F]fluoro‐m‐tyrosine uptake better reflected clinical status than did 6‐[18F]fluoro‐L‐dopa uptake. We attribute this finding to 6‐[18F]fluoro‐m‐tyrosine's higher affinity for the target, L‐aromatic amino acid decarboxylase, and the absence of other major determinants of the uptake rate constant. These results also imply that L‐aromatic amino acid decarboxylase activity is a major determinant of clinical status. © 2011 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Wisconsin</li></region></list><tree><country name="États-Unis"><region name="Wisconsin"><name sortKey="Gallagher, Catherine L" sort="Gallagher, Catherine L" uniqKey="Gallagher C" first="Catherine L." last="Gallagher">Catherine L. Gallagher</name></region><name sortKey="Bendlin, Barbara B" sort="Bendlin, Barbara B" uniqKey="Bendlin B" first="Barbara B." last="Bendlin">Barbara B. Bendlin</name><name sortKey="Bendlin, Barbara B" sort="Bendlin, Barbara B" uniqKey="Bendlin B" first="Barbara B." last="Bendlin">Barbara B. Bendlin</name><name sortKey="Buyan Ent, Laura" sort="Buyan Ent, Laura" uniqKey="Buyan Ent L" first="Laura" last="Buyan-Dent">Laura Buyan-Dent</name><name sortKey="Christian, Bradley T" sort="Christian, Bradley T" uniqKey="Christian B" first="Bradley T." last="Christian">Bradley T. Christian</name><name sortKey="Christian, Bradley T" sort="Christian, Bradley T" uniqKey="Christian B" first="Bradley T." last="Christian">Bradley T. Christian</name><name sortKey="Dejesus, Onofre T" sort="Dejesus, Onofre T" uniqKey="Dejesus O" first="Onofre T." last="Dejesus">Onofre T. Dejesus</name><name sortKey="Gallagher, Catherine L" sort="Gallagher, Catherine L" uniqKey="Gallagher C" first="Catherine L." last="Gallagher">Catherine L. Gallagher</name><name sortKey="Harding, Sandra J" sort="Harding, Sandra J" uniqKey="Harding S" first="Sandra J." last="Harding">Sandra J. Harding</name><name sortKey="Harding, Sandra J" sort="Harding, Sandra J" uniqKey="Harding S" first="Sandra J." last="Harding">Sandra J. Harding</name><name sortKey="Holden, James E" sort="Holden, James E" uniqKey="Holden J" first="James E." last="Holden">James E. Holden</name><name sortKey="Johnson, Sterling C" sort="Johnson, Sterling C" uniqKey="Johnson S" first="Sterling C." last="Johnson">Sterling C. Johnson</name><name sortKey="Johnson, Sterling C" sort="Johnson, Sterling C" uniqKey="Johnson S" first="Sterling C." last="Johnson">Sterling C. Johnson</name><name sortKey="Mueller, Barb" sort="Mueller, Barb" uniqKey="Mueller B" first="Barb" last="Mueller">Barb Mueller</name><name sortKey="Nickles, Robert J" sort="Nickles, Robert J" uniqKey="Nickles R" first="Robert J." last="Nickles">Robert J. Nickles</name><name sortKey="Stone, Charles K" sort="Stone, Charles K" uniqKey="Stone C" first="Charles K." last="Stone">Charles K. Stone</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000408 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000408 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:522EE64365D119496B962B5766EE5C0A818FA428
|texte= A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |